UNSPSC 51412012: Trapidil

This classification denotes a phosphodiesterase inhibitor with the molecular formula C10H15N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EYG5Y6355E, chemically known as 7-diethylamino-5-methyl-s-triazolo(1,5-a)pyrimidine but generally known as trapidil, which bears US NIH Compound Identifier 5531. European Medicines Agency schedules Trapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11220MIG. The term TRAPIDIL is an International Non-Proprietary Name.

UNSPSC 51412012 Trapidil is a Commodity code covering specific pharmaceutical products and active pharmaceutical ingredients used in emergency medical and healthcare delivery. State and local governments procuring under this code are buying branded or generic cardiovascular and emergency medications for fire rescue services, emergency medical services, hospital systems, and state health agencies. The issuing bodies span municipal purchasing departments (fire rescue divisions), state health and human services commissions, and cooperative purchasing alliances representing multiple state and local jurisdictions. Work solicited includes supply contracts for emergency medications meeting FDA and cGMP standards, with vendors required to manage expiration tracking, cold-chain logistics where applicable, warranty coverage, and OSHA-compliant Safety Data Sheets.

Recent activity appears concentrated in Texas and Florida, with multistate cooperative purchasing through Minnesota's MMCAP alliance spanning Oregon and other participating jurisdictions. Representative opportunities include the City of Tampa Fire Rescue's sealed-bid procurement (IFB 26P00188, response due April 8, 2026) for Advanced Life Support Medications including epinephrine, labetalol, adenosine, and diltiazem, estimated at $40,000 and sheltered for Small Local Business Enterprises; the Texas Health and Human Services Commission's Request for Information (RFI HHS0017013, response due April 3, 2026) exploring direct-to-manufacturer prescription fulfillment models; and MMCAP's RFP (S1070000015802, response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, requiring NDC specification, cGMP certification, and DSCSA compliance. Cooperative purchasing vehicles appear alongside traditional municipal IFBs and state RFIs in this code, with contract terms typically running one to two years and renewal options common.